干旱区生态环境知识资源中心(Arid): Ⅲ期非小细胞肺癌术前新辅助化疗的随机对照临床试验

Arid

	Ⅲ期非小细胞肺癌术前新辅助化疗的随机对照临床试验
其他题名	A Randomized Clinical Trial of Preoperative Neoadjuvant Chemotherapy in the Treatment of Stage Ⅲ Non-small Cell Lung Cancer
	姚珂; 向明章; 闵家新; 张国强; 周人杰; 李德志
来源期刊	中国肿瘤临床
ISSN	1000-8179
出版年	2004
卷号	31 期号:11 页码:611-613
中文摘要	目的:探讨术前新辅助化疗治疗Ⅲ期非小细胞肺癌的可行性和不良反应,同时评价其在病期下调率、提高手术切除率及患者生存率中的作用.方法:从1990年1月～2002年1月,对456例Ⅲ期非小细胞肺癌进行前瞻性随机对照试验,234例被随机分入术前新辅助化疗组(试验组),行术前化疗2个周期,其中47例行Gem+DDP方案,35例NVB+DDP方案,86例MVP方案,66例EP方案化疗.化疗结束后4周手术.另222例被随机分入对照组的患者则先行手术治疗.结果:试验组化疗总有效率为67.95%(159/234),病期下调率为35.04%(82/234).手术切除率试验组为87.02%(18l/208),对照组为83.78%(186/222).两组手术并发症和手术死亡率无显著性差异(P＞0.05).新辅助化疗组术后l、3、5年生存率分别为76.07%、52.99%和34.18%,对照组分别为69.82%、41.44%和22.97%.试验组术后生存率显著高于对照组(P＜0.01).结论:术前新辅助化疗安全、有效,能降低Ⅲ期非小细胞肺癌的病期,提高手术切除率,改善患者术后长期生存率和生活质量.
英文摘要	Objective：To explore the feasibilityand toxicity of preoperative neoadjuvantchemotherapy in the treatrlent of slage III NSCLC and to evaluate its effects cm tumor downstaging, resection rate and survied rate. Methods: From January 1990 to Janury 2002, 456 patienls were randomly devided into devided into group A(preoperativ neoadju, allt chemotherapy group)and group B fcontrol group．without neoadjuvant chemotherapy). Group A had 234 cases and group B haci 222 cases. The atients in group A were gave 2 cycles of neoadjuvant chemotherapy, and operations were performed in 4 weeks after finishing the last chemotherapy． All 234 cages were gave intravenous chemotherapy．The regimens ineludecI Gem+DDP in 47 oases．NVB+DDP in 35 cases， MVP in 86cases,and EP in 66 cases. The patients in group B werP fi rstly uperated Results：The tumor response Io induetion rate was 67．95％(159/234) in group A．The tumor dowllstaging was 35．04％I82／234)．The resectin rate was 87．02％ (18/208)in grouIA．anti 83．78％ Il86／222)in gnmp B．No significant diferem·es I.peralive (complications and mortality were observed between the group A and group B．The I-．3- and 5- year survival rate were 76．O7％、52．99％ and 34. 18％ in group A , and 69．82％、41．44% and 22 97％ in group B respectively．The kmg-term su I、aI rate in group A was remarkably hi el"than that in group B( p<0．01). Conclusion：Th preoperative neoadjuvant f-hemotherapy is sa al efective．11 is heIpfijl to decrease the tumor staging，to illcrease tile rection tale of the tumor．and to improve lhe long-term survival rate aim{life qualities afpatienls with slage Ⅲ NSCLC.
中文关键词	非小细胞肺癌 ; 新辅助化疗 ; 生存率
英文关键词	Non-small cell lung cancer neoadjuvant chemotherapy survival rate
语种	中文
国家	中国
收录类别	CSCD
WOS类目	ONCOLOGY
WOS研究方向	Oncology
CSCD记录号	CSCD:1850201
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/205811
作者单位	第三军医大学新桥医院胸外科, 重庆 400037, 中国
推荐引用方式 GB/T 7714	姚珂,向明章,闵家新,等. Ⅲ期非小细胞肺癌术前新辅助化疗的随机对照临床试验[J],2004,31(11):611-613.
APA	姚珂,向明章,闵家新,张国强,周人杰,&李德志.(2004).Ⅲ期非小细胞肺癌术前新辅助化疗的随机对照临床试验.中国肿瘤临床,31(11),611-613.
MLA	姚珂,et al."Ⅲ期非小细胞肺癌术前新辅助化疗的随机对照临床试验".中国肿瘤临床 31.11(2004):611-613.